Please assess the completion status of the following clinical trial:

Trial Title: Atorvastatin in Relapsing-Remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 - 55 years old~* MS diagnosis according McDonald criteria~* Relapsing-remitting MS~* EDSS 0 - 6~* Disease activity as occurrence of CEL in brain MRI~* IFN-beta therapy for at least 6 months~Exclusion Criteria:~* Primary chronic progressive MS~* Symptoms and signs of clinical disease conditions similar to MS~* Conditions that can disturb MRI measurements~* Clinically relevant GI diseases eg Colitis ulcerosa, Crohns disease, history of Ulcus pepticum~* Clinically relevant lung, heart, CNS, infectious disease~* Clinically relevant liver, kidney or bone marrow abnormalities (as defined by specific clinical chemistry values)~* Allergies towards Gd-DTPA~* Allergies towards constituents of the therapeutic agent~* Recruitment to other clinical trials within 6 months prior to or during this study~* Pretreatment with complete lymph irradiation, antibody therapy against lymphocyte populations (eg. anti-CD4, Campath-1H), mitoxantrone, cyclophosphamide, cyclosporin A, human antibodies, all immunomodulatory or immunosuppressive agents including recombinant cytokines or other potential experimental MS therapies (6 months prior to study start), glatiramer acetate, azathioprine, IVIg (6 months prior to study start) pregnancy or lactation~* Alcohol or drug abuse~* Inhibitors of Cytochrom P 450 3A (eg. cyclosporin, macrolide antibiotics, azole antimycotics).~* Medical or psychological conditions that could hamper with the patients capacity to understand patient information, to give the informed consent, to adhere to the protocol of the study and to be able to complete the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- interferon (Type: ACTIVE_COMPARATOR): None
- untreated (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).